OptiScan featured in front page article in Medical Device Daily – “Optiscan’s near continuous multianalyte monitoring device gains CE marking” – January 9, 2017

MANAGE IDE preliminary study results were presented at AAST in September 2016. Grant Bochicchio, primary investigator (Chief, Acute and Critical Care Surgery, Washington University School of Medicine, St Louis), said, “We are excited to have met both primary and secondary endpoints, but even more meaningful is the positive impact this innovation will have on clinical practice and patient outcomes.”

  • Results: Met primary and secondary endpoints of MARD < 10% (actual MARD = 7.6%) and PCV < 13% (actual PCV = 6.5%)

“MANAGE vs automated monitoring accuracy of Glucose II (MANAGE II)” – European study published in Critical Care – 2016 (20:380).

Results: MARD = 7.7%. Clarke Error Grid (CEG) was 99.9% in zones A and B.

OptiScan Biomedical Completes Enrollment of Pivotal U.S. Clinical Study of the OptiScanner 5000 System – November 2015


OptiScan Biomedical has received CE Mark certification for the OptiScanner 5000/6000 system.